| Title | PharmAbcine at JP Morgan Healthcare Conference 2025 |
| Category |
|
PharmAbcine at JP Morgan Healthcare Conference 2025
PharmAbcine, a next-generation antibody therapeutics company, announced on the 10th that it will attend the JP Morgan Healthcare Conference 2025, which will be held from January 13 to 16 (local time) in San Francisco, USA, to engage in discussions on various partnerships. PharmAbcine has been invited to participate in the conference every year since its inception, marking its 16th consecutive attendance this year.
The JP Morgan Healthcare Conference is one of the world's largest healthcare investment events, where pharmaceutical and biotech companies, healthcare professionals, financial institutions, and venture capitalists gather to share the latest therapeutic technologies and explore investment and partnership opportunities.
At this event, PharmAbcine plans to deepen its partnership discussions with global companies, including updates on the Phase 1 clinical trials of PMC-403. Currently, PMC-403 is undergoing a Phase 1 clinical trial in South Korea targeting chronic age-related macular degeneration (AMD) patients who are unresponsive to standard anti-VEGF treatments. Participants in the conference include founder and former CEO Jin-San Yoo, newly appointed CEO Peter Sim, board member Byung-Kyu Kang, and TaeWeon Lee, the CSO of PharmAbcine's U.S. subsidiary, Wincal BioPharm. They are set to actively engage in numerous meetings and networking receptions.
U.S.-based Merck (MSD), which provides Keytruda free of charge for trials involving Olinvacimab, overseen by PharmAbcine's Australian subsidiary, and next-generation immuno-oncology agent PMC-309, has once again extended an invitation to the MSD@JPM Dinner Reception. At this event, CEO Peter Sim will have his first meeting with MSD's C-level executives, marking an important networking opportunity. Jin-San Yoo expressed confidence, stating, “CEO Sim will establish meaningful collaborative relationships based on the company’s long-term growth goals and short-term strategies.”
Despite having joined PharmAbcine less than five months ago, CEO Peter Sim stated that the company’s growth strategies are progressing smoothly. Alongside the JP Morgan Healthcare Conference schedule, he plans to visit the U.S. subsidiary Wincal BioPharm, interact with local staff, and meet with Quan Dong Nguyen, a professor at Stanford University School of Medicine, who plays a key role in the ophthalmology therapeutics division. Wincal BioPharm is developing a new eye-drop platform intended to replace existing intravitreal injection therapies, which has also been selected for an oral presentation at ARVO 2024.
Jin-San Yoo stated, “PMC-403 is more than just a treatment for ophthalmic diseases; it has the potential to serve as a platform for addressing a wide range of vascular dysfunction-related diseases caused by aging, cancer, diabetes, infections, genetic conditions, and injuries.” He added that the company is preparing collaborations with global experts to accelerate the development of this platform. He also shared plans to hold numerous meetings related to this during the JP Morgan Healthcare Conference.
PharmAbcine at JP Morgan Healthcare Conference 2025
PharmAbcine, a next-generation antibody therapeutics company, announced on the 10th that it will attend the JP Morgan Healthcare Conference 2025, which will be held from January 13 to 16 (local time) in San Francisco, USA, to engage in discussions on various partnerships. PharmAbcine has been invited to participate in the conference every year since its inception, marking its 16th consecutive attendance this year.
The JP Morgan Healthcare Conference is one of the world's largest healthcare investment events, where pharmaceutical and biotech companies, healthcare professionals, financial institutions, and venture capitalists gather to share the latest therapeutic technologies and explore investment and partnership opportunities.
At this event, PharmAbcine plans to deepen its partnership discussions with global companies, including updates on the Phase 1 clinical trials of PMC-403. Currently, PMC-403 is undergoing a Phase 1 clinical trial in South Korea targeting chronic age-related macular degeneration (AMD) patients who are unresponsive to standard anti-VEGF treatments. Participants in the conference include founder and former CEO Jin-San Yoo, newly appointed CEO Peter Sim, board member Byung-Kyu Kang, and TaeWeon Lee, the CSO of PharmAbcine's U.S. subsidiary, Wincal BioPharm. They are set to actively engage in numerous meetings and networking receptions.
U.S.-based Merck (MSD), which provides Keytruda free of charge for trials involving Olinvacimab, overseen by PharmAbcine's Australian subsidiary, and next-generation immuno-oncology agent PMC-309, has once again extended an invitation to the MSD@JPM Dinner Reception. At this event, CEO Peter Sim will have his first meeting with MSD's C-level executives, marking an important networking opportunity. Jin-San Yoo expressed confidence, stating, “CEO Sim will establish meaningful collaborative relationships based on the company’s long-term growth goals and short-term strategies.”
Despite having joined PharmAbcine less than five months ago, CEO Peter Sim stated that the company’s growth strategies are progressing smoothly. Alongside the JP Morgan Healthcare Conference schedule, he plans to visit the U.S. subsidiary Wincal BioPharm, interact with local staff, and meet with Quan Dong Nguyen, a professor at Stanford University School of Medicine, who plays a key role in the ophthalmology therapeutics division. Wincal BioPharm is developing a new eye-drop platform intended to replace existing intravitreal injection therapies, which has also been selected for an oral presentation at ARVO 2024.
Jin-San Yoo stated, “PMC-403 is more than just a treatment for ophthalmic diseases; it has the potential to serve as a platform for addressing a wide range of vascular dysfunction-related diseases caused by aging, cancer, diabetes, infections, genetic conditions, and injuries.” He added that the company is preparing collaborations with global experts to accelerate the development of this platform. He also shared plans to hold numerous meetings related to this during the JP Morgan Healthcare Conference.